rly-2608
relay therapeutics
['rly-2608', 'solid tumor']
#aacr23 | chapin theater-convention center | tues
ct017 - pan-mutant and isoform selective pi3k inhibitor, rly-2608, demonstrates selective targeting in a first-in-human study of pik3ca-mutant solid tumor patients, rediscover trial 
The official Twitter account for Mass General Cancer Center, a member of Mass General Brigham.